Hg, the Manager of HgCapital Trust, has announced that it has made an investment in Allocate Software, which it describes as, “a leading international provider of workforce solutions to the healthcare, defence and maritime sectors”. The terms of the transaction were not disclosed. HgCapital Trust plc will invest approximately £14.0 million in Allocate, alongside other institutional clients of Hg that […]
Swiss-listed HBM Healthcare (HBMN) may see a gain from its investment in the private Danish company Y-mAbs Therapeutics, which has filed an S1 registration to raise up to $92m in a Nasdaq IPO. HBM has an 8.2% shareholding in Y-mAbs, which it valued at CHF23m (1.9% of NAV) in its accounts – suggesting the company currently has a CHF280m […]
Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq: ALNY) gained more than 16% yesterday after the presentation of ostensibly highly positive clinical trial data on one of its key competitors at a scientific meeting. Alnylam is held by several of the sector’s specialist investment trusts including Biotech Growth (BIOG, 3.6% of NAV) and BB Biotech (BBB, 3.6% of NAV) […]
BB-backed Ionis hit as FDA rejects Waylivra Shares in Ionis Pharmaceuticals (Nasdaq: IONS), a key shareholding for BB Biotech (10.9% of NAV) and several other specialist investment vehicles, fell by more than 12% after hours yesterday, after the FDA issued a complete response letter (CRL) – effectively a rejection – of its new drug application for Waylivra (volanesorsen). The […]
Standard Life UK Smaller Companies – outperformance, merger and lower fees – the NAV of Standard Life UK Smaller Companies (SLS) delivers a total return of 24.8%, compared with the total return of 8.5% of it’s reference index, the Numis Smaller Companies plus AIM (excluding Investment Companies) Index. Outperformance The company’s performance was good throughout the year in question with a particularly […]
Electra’s Formal Sales Process is closed – but the Strategic Review continues For sometime, Electra Private Equity (ELTA) has been conducting a strategic review on itself. The objective of the review has been to consider all options for the future direction of the company and to implement a strategy to optimise shareholder value. There had been two previous […]
Trust favourite Gilead gears up for filgotinib RA Phase III data Gilead Sciences, a widely held stock among biotech investment trusts and a top 10 holding for BB Biotech (BBB, 5.1% of NAV) and Biotech Growth Trust (BIOG, 3.9%), is expected to report top-line results from two trials involving its JAK 1 selective inhibitor filgotinib in rheumatoid arthritis (RA) and in ankylosing […]
WPCT takes profits on Autolus post IPO share price rise Woodford Patient Capital Trust (WPCT) appears to have taken some profits on its investment in the high-flying second generation CAR-T therapy company, Autolus Therapeutics, through a partial sale of its recently-boosted stake, according to an analysis of trust’s shareholdings in July reported this morning. This is […]
AbbVie exercises option for HBM-backed Argenx antibody Dutch/Belgian antibody company Argenx (Euronext & Nasdaq: ARGX), a top ten holding for Swiss-listed HBM Healthcare (HBMN, 2.6% of NAV) has disclosed that AbbVie has taken up its option to licence the preclinical stage immuno-oncology product ARGX-115. Argenx and AbbVie, a US based pharmaceutical major, entered into an option deal covering ARGX-115 in April […]
WPCT-backed Immunocore enters Phase I with lead GSK project Woodford Patient Capital Trust (WPCT)-backed Immunocore has started a Phase I study of IMCnyeso, the lead engineered T cell product under its collaboration with GlaxoSmithKline (GSK), for a range of cancers. The 63-patient Phase I/II study will assess ImmTAC in patients with non-small cell lung cancer (NSCLC), […]
